• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 29, 2014

View Archived Issues

China's biologics manufacturing: If you build it, will the talent come?

BEIJING – The hot topic at this year's China Bio International 2014 is what type of strategy drugmakers should take to get innovative drugs on the market with China's challenging biologics manufacturing rules. It's clearly a high-stakes gamble, with innovators betting on one of three different horses to get them to the finish line. Read More

Helsinn riding high at ESMO, showcases positive phase III cachexia data

Cancer therapy specialist Helsinn Group reported that anamorelin, its once-daily ghrelin receptor agonist for the common wasting disease cachexia significantly increased lean body mass (LBM) compared to placebo in two phase III trials in non-small-cell lung cancer (NSCLC) patients. Read More

Scenesse up first as EMA pilots patient testimonies in reviews

DUBLIN – The EMA review of Clinuvel Pharmaceuticals Ltd.'s dossier for Scenesse (afamelanotide 16 mg) in the treatment of erythropoietic protoporphyria (EPP) is the first to incorporate patient feedback under a new pilot program. Read More

Immunotherapy holds key to treating melanoma resistance

LONDON – Blocking signals from immune cells could provide a way to prevent melanoma cells from becoming resistant to the latest highly promising therapies. A new study has shown that the cytokine (chemical messenger) TNF-alpha acts as a growth factor for melanoma cells. Not only that, this cytokine attracts additional immune cells to the tumor, which in turn release more TNF-alpha. Read More

Terravab seeks a'whole world' solution to subduing MRSA

With the current Ebola virus outbreak wreaking havoc in West Africa and generating headlines across the world, it's easy to forget that dozens of other pathogens cause even more illness and death around the world. Read More

Regulatory front

The FDA's Office of Prescription Drug Promotion said Friday it is reopening the comment period for the two draft social media guidances published June 17, allowing the public an additional 30 days, beginning Sept. 29, to provide comments. Read More

Financings

Coherus Biosciences Inc., of Redwood City, Calif., filed an S-1 for an initial public offering (IPO) to raise up to $86.3 million, though the number of shares and share price have not yet been disclosed. Read More

Stock movers

Read More

Other news to note

Aveo Oncology Inc., of Cambridge, Mass., took another step to lower operating costs by terminating the lease agreement on its headquarters facility, reducing its lease obligations by $110 million. The amended agreement calls for a payment of $7.8 million at signing and $7.8 million payable over the subsequent nine months. Read More

In the clinic

Microbiome Therapeutics LLC, of Broomfield, Colo., reported top-line results from a proof-of-concept study testing whether investigational drug NM505, a combination of metformin plus the active ingredients in the firm's lead microbiome modulator, NM504, can improve the tolerability of metformin. Read More

Pharma: Other news to note

Daiichi Sankyo Co. Ltd., of Tokyo, said it received approval in Japan for anticoagulant Lixiana (edoxaban) for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for the treatment and recurrence prevention of venous thromboembolism, deep vein thrombosis and pulmonary thromboembolism. Read More

Bench Press: BioWorld looks at translational medicine

Researchers from the University of Kentucky at Lexington have shown that autophagy, a process by which cells recycle cellular components they no longer need, is apparently an important process for maintaining pregnancy. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe